Drug Trial Radar · NCT07662031
Tovecimig Plus FOLFIRI in Second Line Metastatic Colorectal Cancer
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Dec 31, 2026
Primary completion
Dec 31, 2030
Study completion Dec 31, 2032
Sponsor
- Lead sponsor
- Washington University School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Compass Therapeutics
- First posted
- Jun 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label Phase 2 study to evaluate the safety and efficacy of Tovecimig combined with FOLFIRI in patients who have received one prior line of therapy for advanced or metastatic colorectal cancer (CRC).
Conditions
- Colorectal Cancer
- Metastatic Colorectal Cancer
Interventions
TovecimigBiological
Tovecimig is provided in 10 mg/kg dose intravenously over the course of 60 minutes on Day 1 and Day 15 of a 28-day cycle.
IrinotecanDrug
Standard of care irinotecan will be given at a dose of 180 mg/m\^2 intravenously on Day 1 and Day 15 of each 28-day cycle as part of the FOLFIRI treatment regimen.
LeucovorinDrug
Standard of care leucovorin will be given at a dose of 400 mg/m\^2 intravenously on Day 1 and Day 15 of each 28-day cycle as part of the FOLFIRI treatment regimen.
5-Fluorouracil (5-FU)Drug
Standard of care 5-FU will be given at a dose of 2400 mg/m\^2 in continuous infusion over 46 hours on Days 1-2 and Days 15-16 of each 28-day cycle as part of the FOLFIRI treatment regimen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: Start of treatment to completion of treatment (estimated time up to 12 months)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Washington University School of Medicine
St Louis, Missouri
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.